Global Male Infertility Market - 2024-2031

Global Male Infertility Market - 2024-2031

Global Male Infertility market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Male infertility is the condition in which males cannot produce enough sperm (usually below 10 million per milliliter) for fertilization. This can be due to several reasons such as hormonal disorders, inflammation and abnormal development of testicles, injuries, and other unknown causes. The use of alcohol, tobacco, and other drugs also affects the sperm count and quality in many individuals.

Market Dynamics: Drivers & Restraints

Rising prevalence of male infertility

The rising prevalence of male infertility is observed among people in developed countries due to the change in lifestyle and food habits. For instance, according to the National Center for Biotechnology Information, Infertility affects 15% of all couples in the United States and at least 180 million worldwide.

It generally co-exists between the couple hence both are investigated for the cause and treated for the same. Globally, infertility affects more than 13% to 15% of all couples, while one in five is unable to achieve pregnancy during the first year.

According to the World Health Organization, approximately 17.5% of the adult population which is roughly 1 in 6 worldwide experience infertility. The rates differ in high-income and middle-income countries due to the available diagnosis and treatment options. The prevalence was approximately 17.8% in high-income countries and around 16.5% in low- and middle-income countries.

High Cost of the Treatment

Fertility can be achieved artificially by procedures like in vitro fertilization which is a common fertility treatment that involves implantation of the fertilized egg into the uterus of a female. The treatment is rather expensive and the success rate is not so high. For instance, according to Forbes Health, 2023, one single cycle can range from $15,000 to $30,000 depending on the organization's expertise. Hormone treatments are not included in the treatment in most fertility clinics.

Segment Analysisn

The global male infertility market is segmented based on treatment, end user and region.

Intracytoplasmic Sperm Injection (ICSI) Treatment is Expected to Dominate Market

Intracytoplasmic Sperm Injection (ICSI) is often performed along with a combination of IVF. It is a highly valuable treatment for couples suffering from male-factor infertility. Key company strategies such as developments and launches to advance the procedure is expected to drive the market in the forthcoming period.

In November 2023, Femasys Inc. completed enrolling in the LOCAL FemaSeed pivotal clinical trial, designed to evaluate women undergoing FemaSeed cycles due to male factor infertility.

In January 2024, an Australian Medtech company, Fertilis, released a prototype of microICSI, which aims to improve porcine blastocyst development and procedural efficiency for both porcine intracytoplasmic sperm injection and human microinjection.

Furthermore, in July 2023, Thermo Fisher Scientific Inc. released 2 new assays that enable preimplantation genetic testing to improve the ICSI and IVF research.

Geographical Analysis

North America is Expected to Dominate the Global Market

North America is expected to hold the largest share in the segment due to the increasing adoption of IVF procedures in the United States and other parts of North America. For instance, according to the Pew Research Center, in the United States, four in ten adults I.E. 42% of adults likely got the fertility treatment done in their lifetime.

Furthermore, according to the National Center for Biotechnology Information, IVF accounts for approximately 1.6% and 4.5% of all live births in the United States and Europe, respectively. These numbers are on the rise due to the cases of male infertility in United States

Market Segmentation

By Treatment
• Technique
Assisted Reproductive Technology
Intrauterine Insemination (IUI)
In Vitro Fertilization (IVF)
Intracytoplasmic Sperm Injection (ICSI)
• Medication
Estrogen modulators

 Clomiphene citrate

 Anastrozole

 Letrozole

 Others
Human chorionic gonadotropin (hCG)
Others

By End User
• Fertility Clinics
• Hospitals
• Research and Academic institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In January 2024, an Australian Medtech company, Fertilis, released a prototype of microICSI, which aims to improve porcine blastocyst development and procedural efficiency for both porcine intracytoplasmic sperm injection and human microinjection.
• In July 2023, Thermo Fisher Scientific Inc. released 2 new assays that enable preimplantation genetic testing to improve the ICSI and IVF research.
• In November 2023, Femasys Inc. completed enrolling in the LOCAL FemaSeed pivotal clinical trial, designed to evaluate women undergoing FemaSeed cycles due to male factor infertility.

Competitive Landscape

The major global players in the male infertility market include Aytu Bioscience, GeneScience Pharmaceuticals Co., Ltd, Bristol Myers Squibb, Eli Lilly and Company, Halotech DNA, Intas Pharmaceuticals, Bayer Healthcare, Merck KGaA, CinnaGen Co, Vitrolife among others.

Why Purchase the Report?
• To visualize the global male infertility market segmentation based on treatment, end user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of male infertility market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global male infertility market report would provide approximately 50 tables, 47 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies